Category Korus FTA

How did fair use get into the Korean Copyright Act?

As I explained in my previous blog post, the open-ended fair use clause in the Korean Copyright Act (“KCA”) was introduced in 2011 in the course of implementing the Korea-US FTA (“KORUS”). Yet, this does not mean that KORUS mandates legislation of fair use. Instead, KORUS restricts the scope of fair use. Footnote 11 of KORUS §18.4:1 mentions fair use, but it’s purpose is to make clear that any limitation or exception to the reproduction right to temporary storage is restricted to the controversial three-step test, and even when Korea or the US introduces or maintains fair use, the three-step test prevails... Therefore, it is fair to say that the fair use clause of KORUS is a sort of by-product produced in a way that Korean government blinds dark sides of the overly expansive KORUS protection of copyright in temporary storage.

Moderating the Impact of Patent Linkage on Access to Medicines: Lessons from Variations in South Korea, Australia, Canada, and the United States

[Kyung-Bok Son, Ruth Lopert, Deborah Gleeson and Tae-Jin Lee] The inclusion of patent linkage mechanisms in bilateral and plurilateral trade and investment agreements has emerged as a key element in the United States’ TRIPS-Plus intellectual property (IP) negotiating agenda. However, the provisions establishing patent linkage mechanisms in several agreements appear to reflect a degree of ambiguity, potentially enabling some flexibility in their implementation. In this study, we reviewed the features of the prototypic patent linkage mechanism established by the Hatch-Waxman Act in the United States, and compared these with the implementation of systems in three countries whose agreements with the US include patent linkage obligations. From these analyses, we draw lessons for moderating the impact of these mechanisms on access to generic medicines.

Copyright Exceptions, Trade Agreements, and the Digital Economy

PIJIP has researched IP and trade for a while, but we’ve mostly focused on FTAs that included the US.  This year we’ve begun to broaden our view – to look more closely at agreements like RCEP and other Asia-Pacific agreements. This fall we began a detailed comparison of CPTPP, RCEP, CETA, RCEP, EU-Mercosur, EU-Japan, and the China-Korea FTA, with a focus on the copyright and enforcement provisions, and with an eye toward provisions that affect the digital economy. In the last few couple of weeks we’ve begun looking into the provisions in USMCA as well.  This post compares some of the existing text on two provisions: the ‘balance’ provision and protection of TPMs.

Responding to Frequently Asked Questions: TPP TTIP Pharmaceutical Reimbursement “Transparency”

Brand name pharmaceutical companies are advocating for inclusion of disciplines on public pharmaceutical reimbursement programs in the ongoing negotiations of the Trans-Pacific Partnership agreement (TPP) and the Transatlantic Trade and Investment Partnership (TTIP) trade agreements. This post answers some frequently asked questions…